Where does Cytokinetics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cytokinetics, Inc. ranks #5,659 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cytokinetics, Inc. hold?

Cytokinetics, Inc. holds 60 US utility patents granted between 2015 and 2025, spanning 9 technology areas.

What is Cytokinetics, Inc.'s Innovation Score?

Cytokinetics, Inc. has an Innovation Score of 50.3 out of 100 (top 13% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cytokinetics, Inc. focus on?

Cytokinetics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 55 patents, ranking #320 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Cytokinetics, Inc.'s patent grant rate increasing or decreasing?

Cytokinetics, Inc.'s recent grant velocity is +45% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Cytokinetics, Inc.'s patents?

Cytokinetics, Inc.'s patents average 23.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cytokinetics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Cytokinetics, Inc.

USPTO PatentsView assignee record - 60 granted patents across 9 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cytokinetics ranks #5,659 of 49,997 tracked US assignees by granted-patent volume, with 60 patents across 9 technology areas.

#5,659
of 49,997 US assignees by volume: Top 13%
by Innovation Score (50.3/100): 23.1
avg claims per patent: +45%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5659 · US Corporation #5,659 · 60 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 60 grants
UPPER-Q #5,659/49,997
PHOTO-FINISH Automation Anywhere
CPC-NARROW A61P · 9 areas
INNOV-PAR 50.3/100
CLAIMS-DENSE 23.1 claims/avg
TYPE-USCORP US Corporation
VEL-UP +45% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Automation Anywhere, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cytokinetics’s 50.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.2 pts (28%) Velocity 11.7 pts (23%) Breadth 10.6 pts (21%) Claim depth 13.9 pts (28%)

Qualcomm Incorporated · highest

85
Castrol · near

50
Cytokinetics · this assignee

50
Inmar Clearing · near

50
Nautilus Hyosung… · near

50
Unverferth Manufactu… · near

50
3D Lighting… · lowest

7

What this shows Cytokinetics's Innovation Score is 50.3/100 (top 13% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cytokinetics?

Each dot is one of Cytokinetics’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cytokinetics’s own 23.1 claims/patent is ABOVE the 15.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cytokinetics vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cytokinetics's grants concentrate

Cytokinetics, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 91.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (10 grants) versus a trough of 1 in 2016. By volume, Cytokinetics sits between Automation Anywhere, Inc. and Curiouser Products Inc..

Cytokinetics's three-year grant acceleration

Cytokinetics, Inc. shows 21 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Automation Anywhe…

60
Buerkert Werke &…

60
Blackmagic Design…

60
Breathe

60
Cytonome/ST

60
Caraway Home

60
Chelsea Building…

60
Curiouser Products

60
Cytokinetics ◀

60

What this shows Cytokinetics holds 60 patents at rank #5,654, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cytokinetics

By rank, the assignees closest to #5,654 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Cytokinetics's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Cytokinetics, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Cytokinetics ranks #320 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (50 here).

Unverferth Manufacturing Co., Inc. 50 Castrol Limited 50 Inmar Clearing, Inc. 50 Nautilus Hyosung America, Inc. 50

Similar claim depth

Nearest assignees by average claims per patent (23.1 here).

Golba LLC 23.1 avg Adeia Semiconductor Bonding Technologies Inc. 23.1 avg Elta Systems Ltd. 23.1 avg Pregis Innovative Packaging LLC 23.1 avg

Cytokinetics's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

50 Top 13% higher than 87% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Cytokinetics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	7	11.7%
2016	1	1.7%
2017	3	5.0%
2018	5	8.3%
2019	4	6.7%
2020	5	8.3%
2021	3	5.0%
2022	9	15.0%
2023	2	3.3%
2024	10	16.7%
2025partial year	11	18.3%

Which technologies does Cytokinetics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 55

C07D - Heterocyclic Compounds 53

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 25

Y02A - Technologies FOR Adaptation TO Climate Change 9

C07C - Acyclic OR Carbocyclic Compounds 6

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cytokinetics, Inc.'s patent record in context - here's where to go next.

Cytokinetics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 91.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #5,659 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cytokinetics, Inc. against Automation Anywhere, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 50.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.